Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.

Recent News

• Jan 25, 2010
  Threshold Presents Clinical Trial Data From a Phase 1/2 Clinical Trial of TH-302 at ASCO Gastrointestinal Conference
• Jan 12, 2010
  Threshold Pharmaceuticals Provides Clinical Development Update at J.P. Morgan Healthcare Conference

Company Events

January 14, 2010
J.P. Morgan 28th Annual Healthcare Conference

April 18 - 22, 2009
American Association for Cancer Research (AACR) Annual Meeting

May 31, 2009 - View Investor Presentation Webcast
American Society of Clinical Oncology (ASCO) Annual Meeting

April 18 - 22, 2009
American Association for Cancer Research (AACR) Annual Meeting

March 14, 2009
New York Academy of Sciences Conference: Hypoxia and Consequences